Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

The requested reference [2a5e4d2e88d614fc2f082d17d583b99a65c71e63] no longer exists in our database. It has been replaced by the current reference: [49b22b125223289fbf4e97dd8878837de1c8fb7e]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
This is a randomized, double-blind, two-treatment, single-period, parallel design, multiple dose at multiple clinical trial sites designed to demonstrate bioequivalence with clinical endpoint in subjects with chronic open-angle glaucoma or ocular hypertension in both eyes. Test Product - Bimatoprost ophthalmic solution, 0.01% of Amneal EU, Limited Reference Product - LUMIGAN® (bimatoprost ophthalmic solution) 0.01% of Allergan, Inc.
Epistemonikos ID: 57ffdf15b0ca225ccb4fedd3e495237509e5da32
First added on: May 13, 2024